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Abstract
The nonsteroidal anti-inflammatory drugs (NSAIDs) are important class of therapeutic 
agents used for the treatment of pain, inflammation and fever. Nonselective inhibition of 
cyclooxygenase (COX-1 and COX-2) isoenzymes by classical NSAIDs is associated with 
undesirable side effects such as gastrointestinal (GI) and renal toxicities due to COX-1 inhi-
bition. To circumvent this problem, several COX-2 selective inhibitors were developed with 
superior GI safety profile. However, the voluntary market withdrawal of potent COX-2 
selective inhibitors (rofecoxib and valdecoxib) due to their severe cardiovascular toxicity 
which is also found to be associated with some of the traditional NSAIDs suggesting the 
need to relook into the entire class of NSAIDs rather than exclusively victimizing the COX-2 
selective inhibitors. Furthermore, the recent evidences for the involvement of COX-2 selec-
tive inhibitors in the aetiology of many diseases, such as Alzheimer’s disease, Parkinson’s 
 disease, diabetes, various cancers and so on, have gained much attention for researchers to 
design and develop novel COX-2 selective inhibitors with improved pharmacodynamics 
and pharmacokinetic profile. This chapter is focused on the detailed analysis of molecular 
basis of binding interactions of various NSAIDs by highlighting the role of crucial amino 
acid residues at the binding site of cyclooxygenase enzymes (COXs) to be considered for 
selective inhibition of COX-2 enzyme while emphasising the impact of significant CADD 
strategies employed for designing new potent COX-2 inhibitors with tuned selectivity.
Keywords: molecular binding interactions of NSAIDs, computer-aided drug design of 
COX-2 selective inhibitors, development of COX-2 selective inhibitors
© 2017 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
1. Introduction
The nonsteroidal anti-inflammatory drugs (NSAIDs) are important therapeutic agents 
used for the treatment of pain, inflammation and fever [1, 2]. NSAIDs act by reducing the 
production of pro-inflammatory prostaglandins (PGs) at the sites of injury through the 
obstruction of cyclooxygenase enzyme (COX) binding site by sterically preventing the 
binding of the endogenous arachidonic acid (AA) [1–3]. There are two different isoforms 
of COX isoenzymes, a constitutive form (COX-1) and an inducible form (COX-2), respec-
tively [4]. The constitutive COX-1 isozyme plays an important role in many physiological 
functions, such as cytoprotection of gastric mucosa, renal blood flow regulation and plate-
let aggregation. The expression of COX-2 isozyme is mainly induced by several stimuli 
such as hormones, growth factors, mitogens, oncogenes and disorders of water-electrolyte 
homeostasis resulting in its involvement to pathological processes such as inflammation 
and various types of cancer [5]. The classical NSAIDs (aspirin, ibuprofen, flurbiprofen, 
naproxen, indomethacin, diclofenac, mefenamic acid, piroxicam, etc. (Figure 1)) are asso-
ciated with side effects such as gastrointestinal (GI) ulcer and renal toxicity due to their 
nonselective inhibition of COX-1 pathway [6, 7]. As a result, a number of COX-2 selective 
inhibitors such as rofecoxib, celecoxib, valdecoxib and etoricoxib (Figure 2) were intro-
duced into the market as safer NSAIDs which were devoid of GI toxicity. The voluntary 
market withdrawal of rofecoxib (Vioxx) by Merck in September 2004 based on APROVe 
(Adenomatous Polyp Prevention on Vioxx) study followed by valdecoxib (Bextra) in 2005 
(Pfizer) due to their association with increased cardiovascular risk imposed a big  question 
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Figure 1. Representative structures of classical NSAIDs (nonselective COX inhibitors).
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on the safety profile of this class of COX-2  selective inhibitors [8]. Interestingly, no such 
increased cardiovascular risk was observed from the Celecoxib  Long-term Arthritis Safety 
Study (CLASS) trial. Celecoxib (Celebrex) is the only COX-2 selective inhibitor currently 
available in the US market with cautions of cardiac risk. Moreover, some of the nonselec-
tive NSAIDs such as high dosage of diclofenac and ibuprofen are also found to be asso-
ciated with similar incidences of cardiovascular toxicity like COX-2 selective inhibitors 
[9]. Several research findings suggested that the adverse cardiovascular effects of COX-2 
selective inhibitors might be dependent on the dose as well as duration of action [10–12]. 
However, the most potent COX-2 selective inhibitor, lumiracoxib (with different structures 
from other coxibs (Figure 2)), did not exhibit considerable cardiovascular adverse effects 
in Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET) but found 
to be associated with serious hepatic toxicity which resulted in its withdrawal both from 
the Australian and European market [13, 14]. Furthermore, recent studies revealed the 
association of COX-2 with various other pathophysiological processes such as Alzheimer’s 
disease, Parkinson disease, schizophrenia, epilepsy, depression, diabetic peripheral neu-
ropathy and various cancers. [15, 16]. The recognition of new roles for COX-2 selective 
inhibitors imposed a great challenge to the researchers to design and explore alternative 
scaffolds to develop COX-2 selective inhibitors with improved potency and efficacy in order 
to circumvent various side effects associated with the currently available NSAIDs. Thus, a 
detailed analysis of the characteristic structural differences between the two isoenzymes 
along with the binding interactions of different NSAIDs is essential to construct a novel 
structure-based pharmacophore model for designing potent inhibitors with augmented 
COX-2 affinity as well as selectivity. This chapter is focused on the molecular basis of bind-
ing interactions of various NSAIDs by highlighting the role of crucial amino acid residues 
at the binding site of cyclooxygenase enzymes to be considered for  selective inhibition of 
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Figure 2. Structures of COX-2 selective inhibitors.
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COX-2 enzyme while emphasising the impact of  various significant  computer-aided drug 
design (CADD) approaches employed for designing new potent COX-2 inhibitors with 
tuned selectivity.
2. Progress in the pursuit of the development of cyclooxygenase-2 
selective inhibitors
The discovery of the specific role of COX-2 enzyme in inflammation resulted in the devel-
opment of several COX-2 selective inhibitors to overcome the GI side effects of classical 
NSAIDs [15, 16]. Interestingly, before the confirmation of existence of COX-2 enzyme, the 
DuPont company discovered a compound Dup-697 (Figure 2) as a potent anti-inflamma-
tory agent without having the ulcerogenic effects of NSAIDs [17]. After the discovery of 
COX-2 enzyme, Dup-697 became the lead molecule for the development of COX-2 selective 
inhibitors (coxibs); as a result celecoxib and rofecoxib became the pioneer COX-2 selective 
inhibitors to reach the market [18, 19]. Dup-697 is a diaryl heterocyclic compound with 
cis-stilbene moiety. It has been observed from the structure-activity relationship (SAR) 
studies that the diaryl heterocyclic compounds possessing cis-stilbene moiety with varia-
tion in the para-position of one of the aryl rings play an important role in inducing selec-
tivity for COX-2 as compared to COX-1 enzyme [20]. Celecoxib, valdecoxib and parecoxib 
(prodrug of valdecoxib) possess sulphonamide (SO2NH2) group, whereas etoricoxib and rofecoxib have a methyl sulphone (SO2CH3) group at the para-position of one of the aryl rings (Figure 2). Several attempts were made to extensively manipulate the ring system 
that is fused with the cis-stilbene system to include every possible heterocyclic ring of 
varying sizes as well as by altering the scaffolds of classical NSAIDs to convert them 
into COX-2 selective inhibitors, but none could successfully reach the market. Recently, 
a series of thiazole derivatives [21], cycloalkyl/aryl-3,4,5-trimethylgallates [22], thienopy-
rimidine derivatives [23], 3-alkoxy-4-methanesulfonamido acetophenone derivatives [24] 
and 8/10-trifluoromethyl-substituted-imidazo[1,2-c]quinazolines [25], have been designed, 
synthesised and reported from our research group in search of compounds with novel 
scaffold as potent anti-inflammatory agents.
Computer-aided drug design (CADD) strategies have been emerged as a potential tool for the 
discovery of new drugs. In the pursuit of the discovery and development of novel NSAIDs 
with selective inhibition of the COX-2 enzyme, various ligand-based 3D-QSAR and pharma-
cophore models were reported [15]. But these 3D-QSAR models are developed mainly based 
on particular classes of compounds which may not be applicable for the prediction of struc-
turally diverse compounds. In contrast, the structure-based drug design approaches such as 
molecular docking and molecular dynamics (MD) simulation studies are based on detailed 
analysis of the binding site of target protein for designing novel drugs with improved potency. 
The availability of various 3D X-ray crystal structures of COX-1 and COX-2 isoenzymes co-
crystallised with diverse selective and nonselective inhibitors provides an opportunity to 
gain insight into various physicochemical requirements for effective binding of a ligand with 
 selective inhibition of COX-2.
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3. Structural and functional insights of cyclooxygenase enzymes
The COX-1 enzyme is constitutively expressed in most tissues where it is encoded by PTGS-1 
gene (codes for a relatively stable 2.8 kb mRNA). On the other hand, COX-2 is encoded by 
PTGS-2 gene (codes for a relatively less stable 4 kb mRNA), which is activated by several 
inflammatory and proliferative stimuli [3]. The difference in gene expression account for the 
existence of two COX isoforms, signifying that COX-1 provides PGs essential for maintain-
ing homeostasis including gastric cytoprotection, whereas COX-2 plays an important role in 
producing PGs during various pathological conditions such as inflammation and tumouri-
genesis [26]. These observations became the driving force for the rapid development of COX-2 
selective inhibitors having anti-inflammatory activity while avoiding GI side effects associated 
with traditional nonselective NSAIDs.
Human COX-1 and COX-2 enzymes exist as homodimers of 576 and 581 amino acids, respec-
tively, and each monomer having a molecular mass of about 70 kDa [3, 26]. Both enzymes are 
almost identical in their general tertiary structure with 60% sequence similarity. The signal 
peptide of COX-1 is longer (with seven amino acid residues) than COX-2, and the N-terminus 
of COX-1 has an insertion of eight residues, while the C-terminus of COX-2 has an insertion 
of eighteen residues. Each subunit of COX-1 and COX-2 dimers consists of three structural 
domains: the N-terminal epidermal growth factor (EGF) domain (amino acid residues 34–72), 
the α-helical membrane-binding domain (amino acid residues 73–116) and the C-terminal 
catalytic domain, which comprises the bulk of the protein. The catalytic domain contains 
the cyclooxygenase and peroxidase active sites on either side of the heme prosthetic group 
[26–28]. Recent studies revealed that only one monomer of the COX homodimer is active at 
a given time [29]. It has been postulated that these monomers can act additionally through 
an allosteric/catalytic couple, with AA oxygenation being controlled in the ‘catalytic’ mono-
mer (Ecat) through the binding of non-substrate fatty acids and nonselective NSAIDs to the opposite monomer, the ‘allosteric’ monomer (E
allo
) [30, 31]. Moreover, the major differences 
between COX-1 and COX-2 are the substitutions of the bulkier amino acid residues Ile434, 
His513 and Ile523 in COX-1 by comparatively smaller residues Val434, Arg513 and Val523, 
respectively, in COX-2 at the main channel of cyclooxygenase binding site (Figure 3). These 
substitutions produce a 25% increase in the volume of the active site at COX-2 along with 
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the creation of a side pocket off the main channel with Arg513 located at its base [26]. The 
sulphonamide or methyl sulphone moieties of diaryl heterocycle-based coxibs were mainly 
designed to bind within this side pocket to provide selective inhibition of COX-2.
4. Molecular basis of inhibition of cyclooxygenase enzymes and 
computer-aided drug design (CADD) approaches employed for the 
design and discovery of COX-2 selective inhibitors
The experimental methodologies such as site-directed mutagenesis, X-ray crystallographic 
analysis along with various CADD approaches such as structure-based molecular docking 
studies (employing Amber, Flexi dock, Fast dock, Glide), MD simulation, metadynamics 
simulation studies and ligand-based 3D-QSAR (by using COMFA, COMSiA) and pharmaco-
phore modelling were extensively used to understand the molecular basis of interactions of 
NSAIDs with COX enzymes as well as to design novel potent COX-2 selective inhibitors. The 
site-directed mutagenesis and X-ray crystallographic structures of COX-1 and COX-2 isoen-
zymes indicate that selective and nonselective inhibitors generally bind in two different pat-
terns which provides an impetus for the rational modulation of existing binders to improve 
selectivity and potency. It has been observed that the selectivity pocket of COX-1 is compara-
tively smaller due to the presence of bulky amino acid residue Ile523, whereas in COX-2 the 
presence of smaller amino acid residue Val523 enlarged the selectivity pocket providing a 
more stable binding opportunity for selective inhibitors [32, 33]. Further, the kinetics of selec-
tive and nonselective inhibitors were found to be different, and it has been postulated that the 
association of COX-2 selective inhibitor SC-299 with COX-1 and COX-2 occurs at similar rate, 
while the dissociation of SC-299 from COX-2 is 100-fold slower than COX-1 indicating the cor-
relation between the relative rate of dissociation and the selective inhibition of COX-2 isoen-
zyme [34]. This correlation was also confirmed by Walker et al. in additional experiments on 
other COX-2 selective inhibitors [35]. The stable binding mode of selective inhibitors to COX-2 
isoform is also attributed to the presence of a different amino acid residue Val434 instead of 
Ile434 as found in the binding site of COX-1 enzyme.
The active site of COX-2 is mainly hydrophobic where most of the protein-ligand interactions 
are stabilised by van der Waals forces. According to the X-ray crystal structure of COX-2 bound 
with the SC-558 (PDB: 1CX2; 2.5 Å resolution) [33], the ligand binds in the cyclooxygenase 
active site where the bromophenyl ring occupies a hydrophobic pocket formed by Tyr348, 
Phe381, Leu384, Tyr385, Trp387, Gly526, Ala527 and Ser530, respectively (Figure 4). The tri-
fluoromethyl group attached to the pyrazole ring is surrounded by a close hydrophobic cavity 
formed by Met113, Val116, Val349, Tyr355, Leu359 and Leu531 where only Arg120 (located 
near to CF3 group) introduces a strong electrostatic field. This cavity is referred to as common pocket (Figure 4A) as it is also found to be occupied by the aromatic ring bearing the carboxyl-
ate functional group of many nonselective COX inhibitors such as ibuprofen and flurbiprofen, 
respectively [38]. Furthermore, these two features of SC-558 binding are almost equivalent to 
the binding mode of flurbiprofen and indomethacin [33]. The  phenylsulphonamide moiety of 
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Figure 4. (A) 2D X-ray crystallographic pose of SC-558 in COX-2 (unpublished pose taken with the help maestro academic 
visualiser 10.4 [36] by using the crystal structure of COX-2, PDB ID: 1CX2). (B) UBEXTRACT plots (electrostatic, van der 
Waals and total energy) for the interaction of SC-558 with the different residues of the protein (values shown correspond 
to the average of 1.5 ns of MD simulation) (reprinted with permission from Robert et al. [37], copyright © 2003 American 
Chemical Society).
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SC-558 is found to be anchored within a selectivity pocket formed by His90, Asn192, Leu352, 
Ser353, Arg513, Ala516, Ile517, Phe518 and Val523 assuming a conformation in which one 
of the oxygen atoms forms H-bond with Arg513 and is close enough to interact with His90, 
while the amide hydrogens are able to interact with the backbone of Phe518 through two 
water bridges. The phenylsulphonamide moiety of SC-558 is mainly responsible for inducing 
selectivity for COX-2, where it is easily accessible to the selectivity pocket due to the presence 
of smaller residue Val523 that is more restricted in COX-1 because of the substitution of valine 
to isoleucine at the same position-523 [33, 38].
Robert et al. demonstrated the binding mechanism of different NSAIDs (mainly celecoxib and 
rofecoxib analogues) to the cyclooxygenase active site of COX-2 based on molecular dynamics 
(MD) simulation and free energy calculation studies [37]. The MD simulation study carried out 
by using the homology model of human COX-2 also revealed similar binding mode of inter-
action of SC-558 as observed from crystallographic pose [33]. To investigate the key residues 
involved in the interaction of NSAIDs with COX-2, the MD trajectories were analysed by using 
UBEXTRACT programme. For example, the UBEXTRACT analysis [37] indicated that mainly 
four residues (Arg120, Asn192, Leu352 and Arg513) made significant electrostatic interactions, 
whereas thirteen residues involved in van der Waals interaction with the SC-558 (Figure 4B). 
The inspection of experimental data of valdecoxib suggested that the methyl group attached to 
the central isoxazole ring is favourable for binding by making hydrophobic interaction. The MD 
simulation study of rofecoxib [37] showed that the carbonyl group of furanone ring formed an 
H-bond with Ser530. It is interesting to note that to achieve this contact the side chain of Ser530 
adopted a ‘down orientation’, whereas it favours ‘up conformation’ while interacting with cele-
coxib because of water-mediated H-bond between Ser530 and Tyr385 residues (Figure 5A and B).
Vittorio et al. used an advanced metadynamics-based computational technique to simulate the 
full dissociation process of a highly potent and selective inhibitor SC-558 in both COX-1 and 
COX-2 isoenzymes [38]. The metadynamics study of SC-558 dissociation process in COX-2 was 
able to reproduce the X-ray crystallographic pose and also revealed the possibility of an alterna-
tive binding mode (Figure 6A and B). In this alternative binding mode (Figure 6B), the bromo-
phenyl moiety is found to be anchored within a highly hydrophobic cavity formed by Ile345, 
Val349, Leu359, Leu531 and Met535, while the trifluoromethylpyrazole moiety undergone 180° 
rotation which resulted in improved interactions with neighbouring residues such as Leu352, 
Phe518, Val523, Gly526 and Ala527, respectively. Finally, the sulphonamide group engages in 
the formation of H-bond with Tyr355 and Arg120 (Figure 6B). Similar observation is also evident 
from another study where the mutation Tyr355Phe disfavoured the binding of many ligands to 
COX [40]. Further support to this alternative binding mode of SC-558 comes from the very simi-
lar binding mode of some of the experimentally observed nonselective COX inhibitors, in partic-
ular the binding mode of ibuprofen to COX-1 (PDB ID: 1EQG) where the main interactions with 
the protein are well conserved [41]. The carboxylate group of ibuprofen forms polar interactions 
with Tyr355 and Arg120 similarly to the sulphonamide moiety of SC-558 (Figure 6C). In either 
case, the common pocket is occupied by the phenyl ring in ibuprofen and the pyrazole moiety in 
SC-558. The similarity is even greater in case of flurbiprofen or diclofenac, where a halogen atom 
is substituted in the phenyl ring  enforcing the hydrophobic interactions with Leu352, Phe518 
and Val523 similar to trifluoromethyl group of SC-558 (in alternative pose).
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Figure 5. (A) Comparison of the SC-558 and rofecoxib binding modes after superposition of both protein binding sites. 
(B) Details of the rofecoxib binding site when Ser530 is in the ‘up’ (magenta) and in the ‘down’ (green) conformation. The 
conformation found in the crystal structure (brown) is also displayed for comparison (reprinted with permission from 
Robert et al. [37], copyright © 2003 American Chemical Society).
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The experimentally observed time-dependent slow tight-binding inhibition of other diaryl 
heterocyclic compounds similar to SC-558 is interpreted due to the presence of an additional 
binding step, where a vital role might be played by the rearrangement of the hydrogen-bond-
ing network formed by Arg120, Tyr355 and Glu524, respectively, which are assumed to be 
critical for the transition from the relaxed to the tightened state of the enzyme. The involve-
ment of these key residues (Arg120 and Tyr355) in the newly observed alternative binding 
mode of SC-558 suggests that the time-dependent inhibition kinetics of SC-558 results from 
the ability of the ligand to bind in two distinct but equally strong ways [38].
The metadynamics simulation study of SC-558 dissociation process in COX-1 reveals that the 
conformation of SC-558 in COX-1 is very similar to the crystallographic pose of SC-558 in 
COX-2, where the ligand is more weakly bound because of the partial insertion of the sul-
phonamide group into the selectivity pocket of COX-1 due to the presence of bulkier Ile523 in 
contrast to Val523 in COX-2 [38]. Moreover, the presence of the bulkier residue Ile523 in COX-1 
Figure 6. (A) The X-ray crystallographic pose of SC-558 in COX-2 (PDB ID code 1CX2) reproduced during the 
metadynamics simulations. (B) The alternative binding pose of SC-558 in COX-2 found during metadynamics 
simulations. (C) The X-ray binding conformation of ibuprofen in complex with COX-1 (PDB ID code 1EQG). The ligands 
are represented as yellow, whereas the protein is represented as green cartoon with the α-helices forming the gate 
coloured in orange and the hydrogens are not displayed for clarity (reprinted with permission from Vittorio et al. [38]).
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also nullifies the occurrence of alternative binding mode that is observed in case of COX-2 
binding interaction. This hypothesis of selective inhibitors with their high residence time in 
COX-2 due to the existence of additional binding step/mode is also evident from another study 
on a series of COX-2 selective inhibitors [34, 35]. The binding conformation of SC-558 in COX-1 
determined through metadynamics simulation study is very similar to the crystallographic 
pose found for celecoxib in COX-1 [39] with a low RMSD of 1.46 Å for the ligand heavy atoms.
The analysis of X-ray crystallographic binding mode of Vioxx (rofecoxib) with huCOX-2 (PDB 
ID: 5KIR) [42] shows that the inhibitor makes a total of 42 contacts with amino acid residues 
(mainly hydrophobic in nature), while the methyl sulphone moiety occupies the side pocket 
of the cyclooxygenase channel and the phenyl ring extended up towards the side chain of 
Tyr385 (Figure 7A–C). The oxygen (O) atoms of the methyl sulphone moiety of the inhibitor 
Figure 7. Comparison of celecoxib and Vioxx (rofecoxib) bound within the cyclooxygenase channel of COX-2. (A and B) 
Chemical structures of (A) celecoxib and (B) Vioxx. Although both inhibitors share a common diaryl heterocycle scaffold, 
celecoxib contains a pyrazole heterocycle and a sulphonamide moiety, whereas Vioxx contains a furanone heterocycle 
and a methyl sulphone moiety. (C) Stereoview showing an overlay of Vioxx (yellow) and celecoxib (magenta) from 
PDB entry 3LN1 bound within the cyclooxygenase channel of COX-2 (Cα r.m.s.d. of 0.31 A° for 542 pairs). The binding 
mode of the two coxibs is conserved, with the sulphone/sulphonamide moieties penetrating into the COX-2-specific 
side pocket. C-atoms of residues lining the channel are coloured green for huCOX-2 and salmon for muCOX-2, whereas 
N- and O-atoms are coloured blue and red, respectively (reprinted with permission from Orlando and Malkowski [42]).
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made the only significant hydrophilic interactions with the side-chain N-atoms of His90 and 
Arg513, respectively, positioned at the base of the side pocket. It is surprising to note that Vioxx 
is approximately 60-fold more COX-2 selective than celecoxib [43], but it binds in the same 
general conformation as evident from celecoxib binding within the cyclooxygenase active site 
(Figure 7C) [44]. The reason for the difference in COX-2 selectivity between these two inhibi-
tors presumed to be because of their differences in binding kinetics rather than in a particular 
enzyme-inhibitor interaction. Hence, the binding and dissociation kinetic analysis of both Vioxx 
and celecoxib might provide a clear rationale for their different degrees of isoform selectivity.
Further, the X-ray crystallographic pose of celecoxib/ovCOX-1 [39] shows that the Ile523 
propagates a shift of side-chain residues such as His513, Pro514 and Asn515 in the β-turn loop 
of the ‘side pocket’ (Figure 8). The trifluoromethyl (CF3) group attached to the pyrazole ring of celecoxib does not interact with Arg120 typically observed with substrates and other car-
boxylic acid-containing inhibitors. Instead, the trifluoromethyl group adjoins Tyr355 where 
the phenyl ring of Tyr355 makes edge-to-face contact with the aromatic ring of the benzene-
sulphonamide group of celecoxib (Figure 8). It has been also observed that both inhibitors, 
SC-558 and celecoxib, bind in a similar manner with two exceptions. The sulphonamide group 
forms a hydrogen bond with His513 in ovCOX-1 which is Arg513 in muCOX-2. In ovCOX-1, 
the rigid histidine residue does not form a hydrogen bond with celecoxib. The amide nitrogen 
of sulphonamide moiety of celecoxib forms short N─H─O H-bonds with the side chain of 
Gln192 and main chain of Leu352 (Figure 8). Moreover, Ile434 (Val434 in COX-2) is proposed 
to act as a gate to prevent Phe518 from moving away when bound to COX-2 selective inhibi-
tors. As a result, Phe518 forms hydrophobic contacts with the benzene ring of the inhibitor 
in COX-1.
The most commonly used nonselective NSAID, aspirin, covalently modifies COX-1 and 
COX-2 in a time-dependent manner via the acetylation of the hydroxyl group of Ser-530 [45]. 
Figure 8. Celecoxib binding to ovCOX-1 as determined by X-ray crystallography [39] (reprinted with permission from 
Gilad et al. [39]).
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The binding mode of flurbiprofen is found to be identical in both COX-1 and COX-2 (PDB 
ID: 3PGH) isoenzymes [33]. Moreover, it also shows similarity with the binding mode of 
two features of SC-558, where the distal phenyl ring and the fluorophenyl ring of flurbipro-
fen superimpose with the bromophenyl ring and pyrazole ring of SC-558, respectively. In 
contrast, the distal phenyl ring of flurbiprofen forms a π-stacking interaction with Tyr385 
while interacting with Ser530, the residue that is selectively acetylated by aspirin, whereas the 
carboxylate group forms a salt bridge with the guanidine moiety of Arg120 and a hydrogen 
bond with Tyr355, respectively (Figure 9B). Furthermore, the fluorine atom of fluorophenyl 
ring interacts with the side chain of Ile523 in COX-1, which is absent in COX-2 because of the 
presence of a smaller residue valine at the corresponding position-523.
Similarly, the X-ray crystallographic binding mode of another nonselective COX inhibitor, 
indomethacin (PDB ID: 4COX) [33], reveals that it anchors well within the cyclooxygenase 
active site of COX-2 (Figure 9A) by forming a salt bridge between the carboxylate group and 
guanidine moiety of Arg120 (similar to flurbiprofen), while the indole ring mainly  interacts 
with Val349 and Ser353 and forms additional contact with Tyr355, Val523 and Ala527, 
respectively. The six-member ring of indole forms close interaction with Leu352 and Ser353, 
whereas the o-methoxy group protrudes slightly into a relatively large cavity adjacent to 
Ser353, Tyr355 and Val523 in COX-2. The benzoyl group occupies a position very similar to 
that of the distal phenyl ring of flurbiprofen and forms stable hydrophobic interactions with 
Phe381, Leu384, Tyr385 and Trp387, respectively, while the benzoyl oxygen forms H-bonding 
interactions with side-chain hydroxyl group of Ser530 and with Val349, and the chlorine atom 
interacts with Leu384. It has to be noted that the benzoyl ring can adopt either cis or trans 
conformation with respect to indole ring and possibility of cis conformation is claimed to be 
preferable based on the conformation of indomethacin complex with COX-1. It has also been 
anticipated that the benzoyl oxygen plays a vital role in enhancing the affinity for COX-1.
Duggan et al. in their study based on site-directed mutagenesis and X-ray crystallography, 
postulated that the binding mode of naproxen (Figure 9C) is similar to other members of the 
2-arylpropionic acid family of NSAIDs [46]. It is important to note that the majority of 2-aryl-
propionic acid family of NSAIDs are marketed as racemic mixtures except naproxen which 
is exclusively sold as the (S)-enantiomer. The (S)-α-methyl group of naproxen plays a crucial 
role by forming a critical interaction with the COX enzymes and occupies into a hydrophobic 
cleft below Val-349, whereas the removal or substitution of methyl group with a range of 
substituents of varying size and stereochemistry at the α-position results in a dramatic loss 
of potency. The carboxylate group makes hydrogen-bonding interactions with Arg-120 and 
Tyr-355 at the base of the active site. The p-methoxy group of naproxen forms van der Waals 
interactions with Tyr-385 and Trp-387, while the naphthyl moiety of naproxen makes hydro-
phobic interactions with Ala-527, Gly-526 and Leu-352, respectively (Figure 9C). It has been 
observed that the side chain of Leu-352 adopts an alternate conformation as compared to that 
observed in case of binding interactions of co-crystal structures of flurbiprofen, indomethacin 
and diclofenac bound to mCOX-2 (Figure 9A–D) [46].
Comparative analysis of X-ray crystal structures of other 2-arylpropionic acids and the 
diaryl heterocyclic compounds bound to the COX enzymes shows that the α-methyl or 
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4-trifluoromethyl (SC-558) group makes interaction in a similar manner to the naproxen 
[33, 41]. Interestingly, COX inhibitors belonging to carboxylate-containing family without 
having a methyl group in the α-position exploit different interactions to reinforce binding 
within the active site of COX enzymes. For example, diclofenac binds with an inverted 
Figure 9. (A) Binding mode of the crystal structure of indomethacin (PDB ID: 4COX) at the COX-2 active site showing 
H-bonding with constriction residues Arg-120 and Tyr-355 at the base of the active site. (B) Binding mode of the crystal 
structure of flurbiprofen (PDB ID: 3PGH) at the COX-2 active site showing H-bonding with constriction residues Arg-
120 and Tyr-355. (C) Binding mode of the crystal structure of naproxen (PDB ID: 3NT1) at the COX-2 active site showing 
H-bonding with constriction residues Arg-120 and Tyr-355 (similar to indomethacin and flurbiprofen). The inhibitor 
does not enter the side pocket into which the phenyl sulphonamide or phenyl sulphone moieties of diaryl heterocyclic 
compounds protrude. (D) Binding mode of the crystal structure of diclofenac (PDB ID: 1PXX) bound at the COX-2 active 
site showing the opposing binding mode where the position of acidic groups coordinated to the catalytic Tyr-385 as well 
as Ser-530 at the top of the pocket. The inhibitor carbon atoms are coloured green. All the poses were taken with the help 
of maestro academic visualiser 10.4, Schrodinger [36].
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orientation (Figure 9D) where the carboxylate group makes H-bonds with Ser-530 and 
 Tyr-385 and a chlorine atom attached to the lower aniline ring occupies into a hydrophobic 
pocket above Val-349.
Juan et al. carried out docking studies by using the AMBER programme to provide proper 
insights of the differential binding mode of diverse families of COX inhibitors, including 
selective and nonselective ligands: rofecoxib, ketoprofen, suprofen, carprofen, zomepirac, 
indomethacin, diclofenac and meclofenamic, respectively [47]. Their study concluded the 
importance of several structural features that should be attached to a scaffold required for 
efficient COX inhibition such as (i) a carboxylate moiety essential for interaction with the 
Arg120 side chain, (ii) a carbonyl moiety important for making hydrogen bond with the 
side chain of Ser530 and (iii) a distal aromatic ring crucial for fitting into a hydrophobic 
pocket underneath the Tyr385 side chain. Desiraju et al. reported 3D-QSAR models with 
high predictive abilities from a set of 114 substituted 1,2-diarylimidazole analogues for 
computer-aided design of COX-2 selective inhibitors based on 3D-QSAR studies employing 
comparative molecular field analysis (CoMFA) and comparative molecular similarity indi-
ces analysis (CoMSIA) approaches, by including hydrophobic (lipophilic), electrostatic, ste-
ric and hydrogen bond donor and acceptor fields as well as docking studies with FlexiDock 
(using the X-ray crystal structures of COX-1 and COX-2 with PDB ID: 1PGG and 6COX, 
respectively) [48]. Adinarayana et al. studied the interactions of COX-2 active site residues 
with selective inhibitors (rofecoxib, etoricoxib, valdecoxib, celecoxib and its analogues) and 
assessed the importance of scoring functions based on docking studies employing X-score 
scoring function and FastDock programme. The study concluded that the main interac-
tions of COX-2 inhibitors within the binding pocket enzymes are hydrogen bonding and 
hydrophobic interactions indicating that sulphonamide and substituted pyrazole groups 
act as potential pharmacophore features for the design of highly potent and COX-2 selec-
tive inhibitors [49]. Sundar et al. developed a virtual library of drug-like novel molecules 
by employing structure-based de novo drug designing and 2D-fingerprinting approaches 
followed by molecular docking and MD simulation studies and reported two compounds 
as promising highly COX-2 selective inhibitors [50]. Chakraborti et al. in their extensive 
review [15] highlighted various molecular modelling-based approaches in search of novel 
potential COX-2 selective inhibitors overcoming various side effects posed by the drugs in 
clinical use.
Recently, Pfizer Global Research and Development, USA [51], reported their structure-based 
drug design efforts and discovery of two novel orally available benzopyran class of COX-2 
selective inhibitors (SD-8381 and SC-75416, structurally different from the diaryl heterocycle 
class of coxibs (Figure 10)) under clinical trials with superior potency and efficacy as an 
anti-inflammatory and analgesic agent as compared to other NSAIDs and COX-2 selective 
inhibitors. In particular, the compound SC-75416 exhibited a human half-life of 34 h, which 
is suitable for once daily dosing and also demonstrated superior analgesic efficacy in a phase 
II clinical trial of postsurgical dental pain. However, the entire membrane-binding helix 
cluster and the side chain of Tyr355 observed to move ~0.7 and 1.6 Å away from the active 
site to accommodate the bulky 7-t-butyl substituent. The binding orientation of both the 
compounds is very similar to each other and conserves many similar contacts between the 
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enzyme and inhibitor, while the carboxylate group makes H-bond interactions with Tyr385 
and Ser530, respectively.
5. Conclusion
Traditional NSAIDs act by nonselective inhibition of cyclooxygenase isoenzymes and are 
found to be associated with various undesirable side effects such as gastrointestinal (GI) and 
renal toxicity due to COX-1 inhibition. As a result, a number of COX-2 selective inhibitors 
(celecoxib, rofecoxib, valdecoxib, etc.) were developed as safer NSAIDs with improved GI 
safety profile. But the voluntary market withdrawal of rofecoxib and valdecoxib due to their 
strong association with cardiovascular toxicity imposed a big question on the safety pro-
file of COX-2 selective inhibitors. However, similar cardiovascular toxicity was also found 
to be associated with some of the traditional NSAIDs suggesting the need to relook into 
the entire class of NSAIDs rather than exclusively victimising the COX-2 selective inhibi-
tors. Furthermore, the recent evidences for the involvement of COX-2 selective inhibitors in 
the aetiology of many diseases, such as Alzheimer’s disease, Parkinson’s disease, diabetes, 
various cancers, etc. have gained much attention of researchers to design and develop novel 
COX-2 selective inhibitors with improved pharmacodynamic and pharmacokinetic pro-
file. The availability of 3D X-ray crystal structures of cyclooxygenase enzymes (COX-1 and 
COX-2) co-crystallised with diverse selective as well as nonselective inhibitors provides an 
opportunity to gain insight into various physicochemical requirements of ligands for effec-
tive binding with selective inhibition of COX-2 enzyme. The main differences between COX-1 
and COX-2 are found to be the substitutions of the bulkier amino acid residues Ile434, His513 
and Ile523 in COX-1 by comparatively smaller residues Val434, Arg513 and Val523, respec-
tively, in COX-2 at the main channel of cyclooxygenase binding site which resulted in the 25% 
increase in the volume of the active site at COX-2. The advancement of CADD approaches 
made a great impact in the discovery process by facilitating the proper understanding of the 
differential molecular interactions of various inhibitors with cyclooxygenase enzymes. The 
detailed analysis of molecular basis of binding interactions of NSAIDs and various insightful 
CADD approaches discussed in this chapter will be useful to build new strategies to develop 
novel potential COX-2 selective inhibitors to circumvent the limitations associated with the 
NSAIDs in clinical use.
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Figure 10. Chemical structures and biological data of novel benzopyran derivatives SD-8381 and SC-75416 [51].
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